• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Clinically undetectable ovarian and tubal tumors may be present in high-risk patients

byKhang DinhandDavid Wang
September 18, 2014
in Chronic Disease, Obstetrics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. A non-randomized control trial of 996 women at high risk for developing ovarian and tubal cancer found that 2.6% of cases had undetectable neoplasms on pathology after risk-reducing salpingo-oophorectomy.

2. Positive BRCA 1/2 mutation status, older age, postmenopausal status, and abnormal CA-125 levels were associated with clinically undetectable malignancies.

Evidence Rating Level: 3 (Average)

Study Rundown: Carriers of mutations in the BRCA1/2 gene are at higher risk for developing breast and ovarian cancer. In patients with high risk of ovarian cancer, risk-reducing salpingo-oophorectomy (RRSO) have been previously demonstrated to reduce mortality. However, it is not known whether this protection is superior to the traditional CA-125 or transvaginal ultrasound (TVU) screening. In this study, 966 women at high risk of ovarian cancer who elected to have RRSO rather than screening were included. This cohort of patients demonstrated no clinical signs of malignancy and also had CA-125 as well as TVU data available at the time of surgery. Pathology of the surgical specimens demonstrated that 25 patients (2.6%) had clinically undetected ovarian/tubal malignancies. In women who were BRCA1 carriers, BRCA2 carriers, or non-carriers, the rate of occult malignancy was 4.6%, 2.5%, and 0.5%, respectively. The authors also found that elevated CA-125 or abnormal TVU, postmenopausal status, and age were also independently associated with occult neoplasms. Interestingly, 4 of the 25 patients with occult disease had normal screening results, suggesting that there may be a small advantage to RRSO over screening. However, this study was limited in that patients could not be randomized to RRSO, making it very likely that some patients with vague clinical features were preferentially directed to surgery.

Click to read the study in the Journal of Clinical Oncology

Relevant reading: Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation

In-Depth [cross-sectional study]: In this study, standardized pathology results from 966 women from the National Ovarian Cancer Prevention and Early Detection Study (GOG0199) who elected to have RRSO rather than screening were included. 25 patients were found to have occult invasive carcinoma (21) or serous tubal intraepithelial carcinoma (4). Risk of occult malignancy was highest in BRCA1 mutation carriers (4.6%, 95% CI: 2.3-6.9%), followed by BRCA2 mutation carriers (3.5%, 95% CI: 1.1%-5.8%). Only 2 of 403 (0.5%, 95% CI: -0.2-1.2%) non-carriers demonstrated occult malignancy on pathological analysis. Women who were older had higher rates of detected cancers (52.7 years vs 47.1 years, P<0.001). Disease was detected more in postmenopausal women (4.5% vs 1.2%, P = 0.003). Elevated CA-125 and/or abnormal TVU was also associated with higher occult malignancy rates (10.6% vs 1.6%, P<0.001). In multivariate analysis, positive BRCA mutation status (OR: 8.3; 95% CI: 1.9-37.0), postmenopausal status (OR: 4.8, 95% CI: 1.8-13.2), and abnormal CA-125/TVU (OR: 13.8, 95% CI: 5.2-36.3) were independently associated with occult neoplasms at RRSO.

RELATED REPORTS

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma

Maintenance olaparib, compared with placebo, reduces the risk of disease progression in patients with advanced BRCA mutation ovarian cancer

More from this author: Erlotinib does not demonstrate increased survival in ovarian epithelial carcinomas, Afatinib shows increased progression-free survival in non-small-cell lung cancer, New method may predict response to chemotherapy for lung cancer, Escalated-dose radiotherapy did not increase survival in prostate cancer, Stereotactic radiosurgery promising for patients with multiple brain metastases

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: brcaovarian cancer
Previous Post

PET-CT bests contrast CT for response assessment of lymphoma

Next Post

Cardiac MRI predicts degree of heart dysfunction after STEMI

RelatedReports

Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
Oncology

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

March 21, 2022
The SOLO1 trial: Olaparib significantly delays progression of advanced ovarian cancer
Chronic Disease

Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma

February 15, 2022
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Genetics

Maintenance olaparib, compared with placebo, reduces the risk of disease progression in patients with advanced BRCA mutation ovarian cancer

November 2, 2021
#VisualAbstract: Annual screening for ovarian cancer does not significantly reduce mortality
StudyGraphics

#VisualAbstract: Annual screening for ovarian cancer does not significantly reduce mortality

July 18, 2021
Next Post
MRI helps predict risk of local recurrence in upper rectal cancers

Cardiac MRI predicts degree of heart dysfunction after STEMI

3D mammography (tomosynthesis) enhances accuracy of breast cancer screening

Limited benefit to extending breast cancer screening in older women

Aggressive blood pressure control may be beneficial for intracerebral hemorrhage [INTERACT2]

Previous stroke may increase risk of complications after major surgery

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • #VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
  • #VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.